Aliases:This biomarker is also known as:
- 3-hydroxyacyl-CoA dehydrogenase type II,
- Mitochondrial ribonuclease P protein 2,
- Short-chain type dehydrogenase/reductase XH98G2,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- Type II HADH,
- amyloid-beta peptide binding alcohol dehydrogenase,
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- mental retardation, X-linked, syndromic 10,
- mitochondrial RNase P subunit 2,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
- mitochondrial ribonuclease P protein 2,
- 17-beta-HSD 10,
- EC 188.8.131.52,EC 184.108.40.206,
- 17-beta-hydroxysteroid dehydrogenase 10,
- hydroxysteroid (17-beta) dehydrogenase 10,
- short chain dehydrogenase/reductase family 5C, member 1,
- short chain type dehydrogenase/reductase XH98G2,
- AB-binding alcohol dehydrogenase,
- Mitochondrial RNase P protein 2,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.